The higher somatic mutation rate increases the chance that new tumor epitopes will be developed and presented to immune cells via MHC class I.54, 55And higher TMB may be associated with the large number of neoantigens that can be recognized by CD8+ T cells,56 which suggests that patients with high TMB may have a higher response to ICIs. This evidence concerns the gene CD8A and neoplasm.